Advancing American Kidney Health Initiative

ASN Webinar Wednesday, July 24, 2019 2:00 p.m. – 2:45 p.m. EDT



STATE OF KIDNEY HEALTH



Kidney Care in the United States

- Kidney diseases were the 9th leading cause of death in 2017
- Approximately 37,000,000 Americans have kidney diseases
- More than 726,000 Americans have kidney failure
- More than 100,000 Americans begin dialysis each year and nearly 60% of those will die within the first 5 years of treatment
- Nearly 100,000 Americans are on the kidney transplant waiting list



STATE OF KIDNEY HEALTH







EXECUTIVE ACTION




Executive Order on Advancing American Kidney Health

- Signed on Wednesday, July 10 by President Donald J. Trump
- Three major goals:
 - Reduce the risk of kidney failure
 - Improve access to and quality of person-centered treatment options
 - Increase access to kidney transplants







REDUCING RISK



Goal 1: Reducing Risk of Kidney Failure Objectives

- **Objective 1:** Advance public health surveillance capabilities and research to improve identification of populations at risk and those in early stages of kidney disease
- **Objective 2:** Encourage adoption of evidence-based interventions to delay or stop progression to kidney failure



Past and Ongoing Initiatives to Improve **Identification of CKD**

- CKD Surveillance System
- NIH CKD phenotype
- NIH Funded Studies











Future Initiatives to Improve Identification of CKD

- CKD Initiative
 - Cost-effectiveness studies of the long-term efficacy of public health interventions for CKD
 - Systematic Review on Barriers to CKD Screening Project
- CKD Epidemiology in the Military Health System





CONTROL AND PREVENTION




Past and Ongoing Initiatives to Encourage Adoption of Interventions

- Special Diabetes Program for Indians
- National Diabetes Prevention Program
- National Institute of Diabetes and Kidney Diseases promotion of integrated health system model of team-based clinical care
- Medicare Diabetes Prevention Program expanded model



Future Initiatives to Encourage Adoption of Interventions

- Hypertension Control Change Package for Clinicians
- Improving Chronic Diseases Management with Pieces (ICD-Pieces) Study
- ExaHealth









ACCESS AND QUALITY



Goal 2: Improve Access to and Quality of Person-Centered Treatment Options

- **Objective 1.** Improve care coordination and patient education for people living with kidney disease and their caregivers, enabling more person-centric transitions to safe and effective treatments for kidney failure
- **Objective 2.** Introduce new value-based kidney disease payment models that align health care provider incentives with patient preferences and improve quality of life



Past and Ongoing Initiatives to Improve Access and Quality

- Annual U.S. Renal Data System (USRDS) Atlas
- Making Dialysis Safer for Patients Coalition



 ASPR and CMS have formed a collaboration to improve access to dialysis care during every disaster and have launched the emPOWER program

HHS emPOWER Program emPOWERing Communities, Saving Lives



Future Initiatives to Improve Access and Quality Innovation Center's New Kidney Care Models

- Mandatory:
 - End-Stage Renal Disease Treatment Choices (ETC) Model Proposed Rule
- Voluntary:
 - Kidney Care First (KFC) Model
 - Graduated Comprehensive Kidney Care Contracting (CKCC) Model
 - Professional CKCC Model
 - Global CKCC Model



Five Models

ESRD facilities and Managing Clinicians may participate in:

- The KCF Model *or* one of the CKCC Models
- If assigned to the ETC Model, they may still participate in KCF Model or one of the CKCC Models



Proposed Rule for ETC Model

- Mandatory participation for 50% of country
- All Managing Clinicians and all ESRD facilities located in "selected geographic area(s)"
- "Selected geographic area(s)" will be Hospital Referral Regions (HRRs) selected by CMS



Hospital Referral Regions (HRRs)

- 306 HRRs in U.S.
 - All 50 states and District of Columbia, stratified by region: Northeast, South, Midwest, and West (Maryland exception)
- 50% (153) HRRs in intervention group, equal number in comparison group
- Intended to capture 50% of adult ESRD beneficiaries
- HRRs derived from Medicare data based on hospital referral patterns and correlated with dialysis/transplant referral patterns to mitigate potential spillover effects



ETC Model Payment Adjustment Period

Upward or downward performance adjustment on all dialysis claims and dialysis-related claims among the beneficiaries attributed to participating ESRD facilities and Managing Clinicians July 1, 2021 – June 30, 2026, depending on:

- Rates of home dialysis utilization
- Rates of kidney and kidney-pancreas transplantation



ETC Model Payment Adjustments

- Home Dialysis Payment Adjustment (HDPA) would be a + payment adjustment on home dialysis/home dialysis-related claims during initial 3 years of the ETC Model
- <u>Performance Payment Adjustment (PPA)</u> would be a **+ or** payment adjustment, increasing over time, on dialysis/dialysis-related claims, both home and in-center, based on the ETC Participant's home dialysis rates and transplant rates during a Measurement Year in comparison to achievement and improvement benchmarks



Home Dialysis Payment Adjustment (HDPA)

<u>Upward</u> adjustment on the MCP when billed for home dialysis January 1, 2020 – December 31, 2022:

- 3% upward adjustment year one
- 2% upward adjustment year two
- 1% upward adjustment year three



Performance Payment Adjustment (PPA)

Upward <u>or</u> downward performance adjustment on MCP codes billed by Managing Clinicians July 1, 2021 – June 30, 2026, depending on:

- Rates of home dialysis utilization
- Rates of transplantation

Measurement Year (MY) Performance Payment Adjustment (PPA) Period 1/1/2020 through 12/31/2020 PPA Period 1 7/1/2021 through 12/31/2021 MY1 Beginning CY 2020 MY2 7/1/2020 through 6/30/2021 PPA Period 2 1/1/2022 through 6/30/2022 MY3 1/1/2021 through 12/31/2021 PPA Period 3 7/1/2022 through 12/31/2022 Beginning CY 2021 MY4 7/1/2021 through 6/30/2022 PPA Period 4 1/1/2023 through 6/30/2023 MY5 1/1/2022 through 12/31/2022 PPA Period 5 7/1/2023 through 12/31/2023 Beginning CY 2022 MY6 7/1/2022 through 6/30/2023 PPA Period 6 1/1/2024 through 6/30/2024 MY7 1/1/2023 through 12/31/2023 PPA Period 7 7/1/2024 through 12/31/2024 Beginning CY 2023 MY8 7/1/2023 through 6/30/2024 PPA Period 8 1/1/2025 through 6/30/2025 MY9 1/1/2024 through 12/31/2024 PPA Period 9 7/1/2025 through 12/31/2025 Beginning CY 2024 MY10 7/1/2024 through 6/30/2025 PPA Period 10 1/1/2026 through 6/30/2026

TABLE 12: ETC MODEL SCHEDULE OF MEASUREMENT YEARS AND PPA PERIODS



Low-Volume Threshold Exclusions for the PPA

Managing Clinicians:

• CMS proposes excluding Managing Clinicians who fall below the lowvolume threshold of the bottom 5 % of Managing Clinicians in terms of the number of beneficiary-years for which the Managing Clinician billed the MCP during the MY



Low-Volume Threshold Exclusions for the PPA continued

ESRD Facilities:

• CMS proposes excluding ESRD facilities that have fewer than 11 attributed beneficiary-years during a given MY from the application of the PPA meaning that the facility must have at least 132 total attributed beneficiary months for a MY



Risk Adjustment

- For transplant risk adjustment, CMS will use the methodology of the Percentage of Prevalent Patients Waitlisted (PPPW) from the ESRD Quality Incentive Program (QIP) except over 75 years old, in skilled nursing facility, or on hospice
- For risk adjusting home dialysis rates, CMS proposes using the CMS-5 HCC (Hierarchical Condition Category) dialysis model approach



Goal 2: Improve Access to and Quality of Person-Centered Treatment Options

• **Objective 3.** Catalyze the development of innovative therapies including wearable or implantable artificial kidneys with funding from government, philanthropic and private entities through KidneyX, and coordinating regulatory and payment policies to incentivize innovative product development



Ongoing and Future Initiatives to Improve Access and Quality Focusing on Innovative Product Development

- Catalyzing rapid product development through public-private partnerships (particularly KidneyX)
- Creating clear and forward-looking guidelines for marketing approval for emerging technologies
- Prioritizing development of an artificial kidney in KidneyX Redesign Dialysis Phase III
- Providing next-generation organ preservation devices and systems



Goal 3: Increase Access to Kidney Transplants

- **Objective 1.** Increase the utilization of available organs from deceased donors by increasing organ recovery and reducing the organ discard rate
- **Objective 2.** Increase the number of living donors by removing disincentives to donation and ensuring appropriate financial support



Future Initiatives to Improve Deceased Donation

- Revising the guidelines to reducing risk of HIV, HBV, and HCV transmission while preserving high-quality organs
- Organizing a workshop to discuss use of HCV+ donor organs in recipients who do not have HCV
- Testing accelerated placement of kidneys at high risk for discard
- Reviewing the OPO conditions for coverage and proposing changes to the standards used to evaluate OPOs



Future Initiatives to Improve Living Donation

- Expanding reimbursement of travel and other expenses related to living organ donation
- Considering also providing reimbursement for lost wages for donors
- Using findings from two ongoing HRSA studies to inform these decisions



QUESTIONS?

